Literature DB >> 33926468

A heparin-rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis.

Yingjun Liu1,2,3,4, Peixi Liu1,2,3,4, Yaying Song5,6, Sichen Li1,2,3,4, Yuan Shi1,2,3,4, Kai Quan1,2,3,4, Guo Yu1,2,3,4, Peiliang Li7,8,9,10, Qingzhu An11,12,13,14, Wei Zhu15,16,17,18.   

Abstract

BACKGROUND: An endovascular covered-stent has unique advantages in treating complex intracranial aneurysms; however, in-stent stenosis and late thrombosis have become the main factors affecting the efficacy of covered-stent treatment. Smooth-muscle-cell phenotypic modulation plays an important role in late in-stent stenosis and thrombosis. Here, we determined the efficacy of using covered stents loaded with drugs to inhibit smooth-muscle-cell phenotypic modulation and potentially lower the incidence of long-term complications.
METHODS: Nanofiber-covered stents were prepared using coaxial electrospinning, with the core solution prepared with 15% heparin and 20 µM rosuvastatin solution (400: 100 µL), and the shell solution prepared with 120 mg/mL hexafluoroisopropanol. We established a rabbit carotid-artery aneurysm model, which was treated with covered stents. Angiography and histology were performed to evaluate the therapeutic efficacy and incidence rate of in-stent stenosis and thrombosis. Phenotype, function, and inflammatory factors of smooth-muscle cells were studied to explore the mechanism of rosuvastatin action in smooth-muscle cells. RESULT: Heparin-rosuvastatin-loaded nanofiber scaffold mats inhibited the proliferation of synthetic smooth-muscle cells, and the nanofiber-covered stent effectively treated aneurysms in the absence of notable in-stent stenosis. Additionally, in vitro experiments showed that rosuvastatin inhibited the smooth-muscle-cell phenotypic modulation of platelet-derived growth factor-BB induction and decreased synthetic smooth-muscle-cell viability, as well as secretion of inflammatory cytokines.
CONCLUSION: Rosuvastatin inhibited the abnormal proliferation of synthetic smooth-muscle cells, and heparin-rosuvastatin-loaded covered stents reduced the incidence of stenosis and late thrombosis, thereby improving the healing rates of stents used for aneurysm treatment.

Entities:  

Keywords:  Intracranial aneurysm; Late thrombosis; Long-term arterial stenosis; Nanofiber-covered stent; Rosuvastatin

Year:  2021        PMID: 33926468     DOI: 10.1186/s12951-021-00867-8

Source DB:  PubMed          Journal:  J Nanobiotechnology        ISSN: 1477-3155            Impact factor:   10.435


  61 in total

1.  International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial.

Authors:  Andrew Molyneux; Richard Kerr; Irene Stratton; Peter Sandercock; Mike Clarke; Julia Shrimpton; Rury Holman
Journal:  Lancet       Date:  2002-10-26       Impact factor: 79.321

Review 2.  Unruptured intracranial aneurysms: development, rupture and preventive management.

Authors:  Nima Etminan; Gabriel J Rinkel
Journal:  Nat Rev Neurol       Date:  2016-11-03       Impact factor: 42.937

3.  Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment.

Authors:  David O Wiebers; J P Whisnant; J Huston; I Meissner; R D Brown; D G Piepgras; G S Forbes; K Thielen; D Nichols; W M O'Fallon; J Peacock; L Jaeger; N F Kassell; G L Kongable-Beckman; J C Torner
Journal:  Lancet       Date:  2003-07-12       Impact factor: 79.321

4.  Endovascular treatment of posterior circulation aneurysms by electrothrombosis using electrically detachable coils.

Authors:  G Guglielmi; F Viñuela; G Duckwiler; J Dion; P Lylyk; A Berenstein; C Strother; V Graves; V Halbach; D Nichols
Journal:  J Neurosurg       Date:  1992-10       Impact factor: 5.115

Review 5.  Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms: a pooled analysis of six prospective cohort studies.

Authors:  Jacoba P Greving; Marieke J H Wermer; Robert D Brown; Akio Morita; Seppo Juvela; Masahiro Yonekura; Toshihiro Ishibashi; James C Torner; Takeo Nakayama; Gabriël J E Rinkel; Ale Algra
Journal:  Lancet Neurol       Date:  2013-11-27       Impact factor: 44.182

6.  Endovascular treatment of giant intracranial aneurysms with willis covered stents: technical case report.

Authors:  Jian B Wang; Ming H Li; Chun Fang; Wu Wang; Ying S Cheng; Pei L Zhang; Zhuo Y Du; Jue Wang
Journal:  Neurosurgery       Date:  2008-05       Impact factor: 4.654

7.  A novel flow-diverting device (Tubridge) for the treatment of 28 large or giant intracranial aneurysms: a single-center experience.

Authors:  Y Zhou; P-F Yang; Y-B Fang; Y Xu; B Hong; W-Y Zhao; Q Li; R Zhao; Q-H Huang; J-M Liu
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-10       Impact factor: 3.825

8.  Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis.

Authors:  Dennis J Nieuwkamp; Larissa E Setz; Ale Algra; Francisca H H Linn; Nicolien K de Rooij; Gabriël J E Rinkel
Journal:  Lancet Neurol       Date:  2009-06-06       Impact factor: 44.182

9.  International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion.

Authors:  Andrew J Molyneux; Richard S C Kerr; Ly-Mee Yu; Mike Clarke; Mary Sneade; Julia A Yarnold; Peter Sandercock
Journal:  Lancet       Date:  2005 Sep 3-9       Impact factor: 79.321

Review 10.  The implications of ISAT and ISUIA for the management of cerebral aneurysms during pregnancy.

Authors:  Laurence A G Marshman; A Robert Aspoas; Manjit S Rai; Sanjiv J Chawda
Journal:  Neurosurg Rev       Date:  2007-05-17       Impact factor: 2.800

View more
  5 in total

1.  An in situ tissue engineering scaffold with growth factors combining angiogenesis and osteoimmunomodulatory functions for advanced periodontal bone regeneration.

Authors:  Tian Ding; Wenyan Kang; Jianhua Li; Lu Yu; Shaohua Ge
Journal:  J Nanobiotechnology       Date:  2021-08-17       Impact factor: 10.435

2.  Transcriptome-Based Dissection of Intracranial Aneurysms Unveils an "Immuno-Thermal" Microenvironment and Defines a Pathological Feature-Derived Gene Signature for Risk Estimation.

Authors:  Taoyuan Lu; Zaoqu Liu; Dehua Guo; Chi Ma; Lin Duan; Yanyan He; Rufeng Jia; Chunguang Guo; Zhe Xing; Yiying Liu; Tianxiao Li; Yingkun He
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

Review 3.  Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies.

Authors:  Li Li; Sainan Liu; Jianying Tan; Lai Wei; Dimeng Wu; Shuai Gao; Yajun Weng; Junying Chen
Journal:  J Tissue Eng       Date:  2022-03-24       Impact factor: 7.813

4.  Macrophage membrane camouflaged reactive oxygen species responsive nanomedicine for efficiently inhibiting the vascular intimal hyperplasia.

Authors:  Boyan Liu; Wenhua Yan; Li Luo; Shuai Wu; Yi Wang; Yuan Zhong; Dan Tang; Ali Maruf; Meng Yan; Kun Zhang; Xian Qin; Kai Qu; Wei Wu; Guixue Wang
Journal:  J Nanobiotechnology       Date:  2021-11-17       Impact factor: 10.435

5.  Single-Cell RNA Sequencing Reveals the Pathogenic Relevance of Intracranial Atherosclerosis in Blood Blister-Like Aneurysms.

Authors:  Dingke Wen; Xing Wang; Ruiqi Chen; Hao Li; Jun Zheng; Wei Fu; Tianjie Zhang; Mu Yang; Chao You; Lu Ma
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.